

John E. Flaherty  
Ravin R. Patel  
McCARTER & ENGLISH LLP  
Four Gateway Center  
100 Mulberry St.  
Newark, NJ 07102  
(973) 622-4444

*Attorneys for Plaintiff Horizon  
Therapeutics, Inc.*

Dennis A. Bennett  
Tim Burgdorf  
GLOBAL PATENT GROUP, LLC  
1005 North Warson Road, Suite 404  
St. Louis, Missouri 63132  
(314) 812-8020

Robert F. Green  
Emer L. Simic  
Ann K. Kotze  
GREEN GRIFFITH & BORG-BREEN LLP  
NBC Tower, Suite 3100  
455 North Cityfront Plaza Drive  
Chicago, Illinois 60611  
(312) 883-8000

*Of Counsel for Plaintiff Horizon  
Therapeutics, Inc.*

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

HORIZON THERAPEUTICS, INC.,

*Plaintiff,*

v.

LUPIN LTD. and LUPIN  
PHARMACEUTICALS, INC.,

*Defendants.*

Civil Action No. 1:15-CV-07624-  
RBK-JS

**AMENDED COMPLAINT**

Plaintiff Horizon Therapeutics, Inc., by its undersigned attorneys, brings this action against Defendants Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, “Defendants” or “Lupin”), and hereby allege as follows:

**NATURE OF THE ACTION**

1. This is an action for patent infringement under the patent laws of the United States, Title 35 of the United States Code, arising from Defendants’ filing of an Abbreviated

New Drug Application (“ANDA”) with the United States Food and Drug Administration (“FDA”) seeking approval to market a generic version of Plaintiff’s pharmaceutical product RAVICTI® (glycerol phenylbutyrate) (“RAVICTI®”) prior to the expiration of United States Patent No. 9,095,559 (“the ’559 patent”).

### **THE PARTIES**

2. Plaintiff Horizon Therapeutics, Inc. is a corporation organized and existing under the laws of the State of Delaware, with a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045.

3. On information and belief, Defendant Lupin Limited (“Lupin Ltd.”) is a corporation operating and existing under the laws of India, having a principal place of business at B/4 Laxmi Towers, Bandra Kurla Complex, Bandra (E), Mumbai 400 051, India, and its registered office at 159 CST Road, Kalina, Santacruz (E), Mumbai 400 098, India.

4. On information and belief, Lupin Ltd. is in the business of, *inter alia*, developing, manufacturing, obtaining regulatory approval, marketing, selling, and distributing generic copies of branded pharmaceutical products throughout the United States, including within this judicial district, through its own actions.

5. On information and belief, Defendant Lupin Pharmaceuticals Inc. (“LPI”) is a corporation operating and exiting under the laws of the Commonwealth of Virginia, with its principal place of business at 111 South Calvert Street, 21<sup>st</sup> Floor, Baltimore, MD 21202.

6. On information and belief, LPI is in the business of, *inter alia*, manufacturing, obtaining regulatory approval, marketing, selling, and distributing generic copies of branded pharmaceutical products throughout the United States, including within this judicial district, through its own actions and through the actions of its agents and subsidiaries.

7. On information and belief, LPI is a wholly-owned subsidiary of Lupin Ltd.
8. On information and belief, LPI is registered with the State of New Jersey as a wholesale distributor under Registration Number 5004060.
9. On information and belief, LPI is registered with the State of New Jersey, Division of Revenue and Enterprise Services, as Entity No. 0100953673.
10. On information and belief, LPI acts at the direction of, under the control of, and for the benefit of Lupin Ltd. and is controlled and/or dominated by Lupin Ltd.
11. On information and belief, Lupin Ltd. and LPI have at least one officer and/or director in common.
12. On information and belief, Defendants participated and collaborated in the research and development, and the preparation and filing, of ANDA No. 207694 (“the Lupin ANDA”) for glycerol phenylbutyrate oral liquid (“the Lupin Product”), continue to participate and collaborate in seeking FDA approval of that application, and intend to participate and collaborate in the commercial manufacture, marketing, offer for sale and sale of the Lupin Product throughout the United States, including in the State of New Jersey, in the event the FDA approves Lupin’s ANDA.
13. On information and belief, LPI is the US agent for Lupin Ltd. in connection with the filing of the Lupin ANDA with the FDA and subsequent FDA communications relating thereto.
14. On information and belief, should the Lupin ANDA be finally approved by FDA, LPI will sell, offer for sale and distribute the Lupin Product throughout the United States, including within this judicial district.
15. On information and belief, Lupin Ltd. and LPI have availed themselves of the

rights, benefits and privileges of this Court by filing at least one complaint for patent infringement in the District of New Jersey: *Lupin Ltd., et al. v. Merck, Sharp & Dohme Corp.*, Civil Action No. 3:10-cv-00683.

16. On information and belief, Lupin Ltd. and LPI have admitted to, consented to or have not contested, the jurisdiction of this Court in at least five prior District of New Jersey actions: *Senju Pharmaceutical Co., Ltd., et al. v. Lupin Ltd., et al.*, Civil Action No. 1:15-cv-00335, *Senju Pharmaceutical Co., Ltd., et al. v. Lupin Ltd., et al.*, Civil Action No. 1:14-cv-05144, *Janssen Products, L.P., et al. v. Lupin Ltd., et al.*, Civil Action No. 2:14-cv-01370, *Takeda Pharmaceutical Co. Ltd., et al. v. Lupin Ltd., et al.*, Civil Action No. 3:12-cv-07333, and *AstraZeneca Pharmaceuticals LP, et al. v. Lupin Ltd., et al.*, Civil Action No. 3:12-cv-06888.

17. On information and belief, Lupin Ltd. and LPI have availed themselves of the rights, benefits and privileges of this Court by asserting counterclaims in at least five prior District of New Jersey actions: *Senju Pharmaceutical Co., Ltd., et al. v. Lupin Ltd., et al.*, Civil Action No. 1:15-cv-00335, *Senju Pharmaceutical Co., Ltd., et al. v. Lupin Ltd., et al.*, Civil Action No. 1:14-cv-05144, *Janssen Products, L.P., et al. v. Lupin Ltd., et al.*, Civil Action No. 2:14-cv-01370, *Takeda Pharmaceutical Co. Ltd., et al. v. Lupin Ltd., et al.*, Civil Action No. 3:12-cv-07333, and *AstraZeneca Pharmaceuticals LP, et al. v. Lupin Ltd., et al.*, Civil Action No. 3:12-cv-06888.

### **JURISDICTION AND VENUE**

18. This Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331 and 1338(a).

19. This Court has personal jurisdiction over Defendants by virtue of, *inter alia*, their presence in New Jersey, having conducted business in New Jersey, having availed themselves of

the rights and benefits of New Jersey law such that they should reasonably anticipate being haled into court in this judicial district, previously submitting to personal jurisdiction in this Court, availing themselves of the jurisdiction of this Court (*e.g.*, by the assertion of claims and counterclaims), and having engaged in systematic and continuous contacts with the State of New Jersey through the marketing and sales of generic drugs throughout the United States, and in particular within this judicial district, through the receipt of revenue from the sales and marketing of generic drug products, including Lupin products, within this judicial district, and through their intent to market and sell the Lupin Product, if approved, to residents of this judicial district.

20. Venue is proper in this judicial district under 28 U.S.C. §§ 1391(b) and (c) and § 1400(b).

#### **THE PATENT-IN-SUIT**

21. On August 4, 2015, the USPTO duly and legally issued the '559 patent entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs." At the time of its issue, the '559 patent was assigned to Horizon Therapeutics, Inc. Horizon Therapeutics, Inc. currently is the sole assignee and owner of all right, title and interest in and to the '559 patent, which claims methods related to the treatment of urea cycle disorder patients with glyceryl tri-[4-phenylbutyrate] based on measurement of fasting blood ammonia blood levels. A true and correct copy of the '559 patent is attached hereto as Exhibit A.

#### **RAVICTI®**

22. Horizon Therapeutics, Inc. is the owner of FDA-approved New Drug Application No. 203284 ("the RAVICTI® NDA") for glycerol phenylbutyrate oral liquid 1.1gm/ml, which is sold by Horizon Pharma USA, Inc. in the US under the tradename RAVICTI®.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.